Mei-Ting Lin

Mei-Ting Lin

Auto-generated profile, based on publicly available information

Mei-Ting Lin

National Tsing Hua University 101, Section 2, Kuang-Fu Road

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2026 in ACS Synthetic Biology
Verified
Journal Article
Open access
CLCheng-Huan Liu
Cheng-Huan Liu
KOKai-Eng Ooi
Kai-Eng Ooi
MLMei-Ting Lin
Mei-Ting Lin
YCYung-Jen Cheng
Yung-Jen Cheng
GWGuan-Chun Wu
Guan-Chun Wu
CYChing-Ching Yu
Ching-Ching Yu
Fucosylated human milk oligosaccharides (HMOs) are important bioactive glycans, but their biosynthetic production requires fucosyltransferases with predictable acceptor selectivity to avoid regioisomer formation and downstream purification burdens. Here we identify an α1,3-fucosyltransferase from Akkermansia muciniphila (AkkFT) that functions as a lactose-selective α1,3-fucosylation module for HMO synthesis. AkkFT preferentially acts on glycans containing a lactose unit and shows no detectable conversion of type-1 or type-2 N-acetyllactosamine acceptors under standard conditions, contrasting with commonly used bacterial α1,3/4-fucosyltransferases. This lactose-anchored selectivity enables late-stage α1,3-fucosylation across neutral and sialylated HMO acceptors, including efficient formation of lacto-N-neofucopentaose V and the blood group B antigen. Notably, AkkFT converts disialyl-lacto-N-tetraose to disialyl-lacto-N-fucopentaose V under conditions where Helicobacter pylori α1,3-fucosyltransferases show no detectable activity. AkkFT also converts free 2′-fucosyllactose to lactodifucotetraose on a preparative scale and was implemented in an engineered Escherichia coli strain for whole-cell 3-fucosyllactose production. Overall, AkkFT expands the repertoire of selectivity-defined biosynthetic parts for fucosylated HMO production and demonstrates how enzyme discovery can complement engineered microbial platforms for glycan biomanufacturing.

20 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CPChuanhao Peng
Chuanhao Peng
SHSimatsidk Haregu
Simatsidk Haregu
CYClaire Yi-Ling Yang
Claire Yi-Ling Yang
SGShreyas Gupta
Shreyas Gupta
MEMichael Evgen
Michael Evgen
RDRatmir Derda
Ratmir Derda
Recent synthesis of essential enzymes, such as DNA and RNA polymerases with opposite chirality, has boosted the feasibility of creating mirror-image life. Such life, if ever produced, will undoubtedly be coated by a dense display of glycans (glycoproteins, glycolipids, polysaccharides) built from enantiomers of common monosaccharides. Recognition of mirror-image glycans by extant glycan-binding proteins (GBPs) may be critical for colonization by or immune response to mirror life organisms. We evaluated recognition of enantiomers of common glycans by a diverse set of purified GBPs (plant and human derived), antibodies (including IgM from human plasma), mammalian cells (including immune cells), and organs in live animals. We found that GBP binding to enantiomers of naturally prevalent glycans is widespread. Notably, L-glucose and L-galactose interact with fucose-binding lectins, including DC-SIGN, a C-type lectin expressed on immune cells. These interactions can be inhibited by soluble “natural” glycan ligands and enantiomeric ones confirming specificity. Binding of L-glycans to diverse immune cell repertoires revealed preferences for specific glycan enantiomers. IgM antibodies from human serum showed donor-specific recognition of L-glycans. We propose that the recognition of L-glycans by extant GBPs arises from their co-evolution over millennia with the L-glycans that are present in the glycocalyx of many microorganisms.